Pınar D Gündoğmuş, İbrahim Gündoğmuş, Emrah Burak Olcu, A. Karagoz, A. Algul
Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report Cardiotoxicity is an important adverse effect of some psychotropic drugs. However, cardiac side effects with mirtazapine, which is used for an effective treatment of depression and anxiety, are rare. In this article, a forty-eight-year-old woman referred to psychiatric clinics with depressive symptoms. According to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria, major depressive disorder was diagnosed and mirtazapine 30mg/day was started. 30 minutes after the first dose of mirtazapine was brought to the emergency room with syncope, nausea, vomiting. She was examined in emergency service. Routine blood tests and ECG was studied. During the examination, the patient was followed up with a heart rate of 33 beats per minute, blood pressure arterial 80/50mmHg and a temperature of 36.1°C. 0.5mg atropine IV and theophylline inhaler were administered and cardiology consultation was requested. After atropine and theophylline administration, the heart rate was 48 beats/min in the second ECG. To the best of our knowledge, it is the first bradycardia developed after mirtazapine use in the literature. Bradycardia has been resolved after the half-life of mirtazapine has passed (37 hours for women). The initial heart rate of our patient was within normal limits prior to mirtazapine administration. There was no reason to explain bradycardia, we think that symptomatic bradycardine is caused by mirtazapine. In conclusion, this case report suggests that mirtazapine may cause bradycardia in patients. Risk factors for bradycardia caused by mirtazapine are unknown. Although in many patients this bradycardine does not cause a clinical outcome, clinicians should be aware of this and should perform ECG monitoring in patients with underlying cardiac disease, especially when prescribing mirtazapine.
{"title":"Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report","authors":"Pınar D Gündoğmuş, İbrahim Gündoğmuş, Emrah Burak Olcu, A. Karagoz, A. Algul","doi":"10.5350/dajpn2018310309","DOIUrl":"https://doi.org/10.5350/dajpn2018310309","url":null,"abstract":"Therapeutic single-dose mirtazapine-induced symptomatic bradycardia: a case report Cardiotoxicity is an important adverse effect of some psychotropic drugs. However, cardiac side effects with mirtazapine, which is used for an effective treatment of depression and anxiety, are rare. In this article, a forty-eight-year-old woman referred to psychiatric clinics with depressive symptoms. According to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria, major depressive disorder was diagnosed and mirtazapine 30mg/day was started. 30 minutes after the first dose of mirtazapine was brought to the emergency room with syncope, nausea, vomiting. She was examined in emergency service. Routine blood tests and ECG was studied. During the examination, the patient was followed up with a heart rate of 33 beats per minute, blood pressure arterial 80/50mmHg and a temperature of 36.1°C. 0.5mg atropine IV and theophylline inhaler were administered and cardiology consultation was requested. After atropine and theophylline administration, the heart rate was 48 beats/min in the second ECG. To the best of our knowledge, it is the first bradycardia developed after mirtazapine use in the literature. Bradycardia has been resolved after the half-life of mirtazapine has passed (37 hours for women). The initial heart rate of our patient was within normal limits prior to mirtazapine administration. There was no reason to explain bradycardia, we think that symptomatic bradycardine is caused by mirtazapine. In conclusion, this case report suggests that mirtazapine may cause bradycardia in patients. Risk factors for bradycardia caused by mirtazapine are unknown. Although in many patients this bradycardine does not cause a clinical outcome, clinicians should be aware of this and should perform ECG monitoring in patients with underlying cardiac disease, especially when prescribing mirtazapine.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"87 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87690730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The effect of heroin use disorder on the sexual functions of women Objective: This study was conducted to evaluate the sexual functions of women with heroin use disorder. Method: This comparative-descriptive and cross-sectional study was carried out at the Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM) of Bakirkoy Training and Research Hospital for Psychiatry Neurology and Neurosurgery. Included in the heroin use disorder group were 57 women aged 18 years or above who presented to AMATEM between June 1, 2014 and December 31, 2014 and received a diagnosis of substance use disorder according to DSM-5. Inclusion criteria were the absence of psychiatric diseases, substance withdrawal symptoms, or mental retardation, being sexually active, not being pregnant or puerperant, and having given consent to participate in the study. Healthy female relatives of 79 female patients who presented to the Gynecology Clinic of the same hospital during the same period were included in the healthy group. The data were collected through an interview form was developed by researchers, Female Sexual Function Index (FSFI), and Beck Depression Inventory (BDI). Results: No difference was determined between the participants in both groups in terms of average age, period of education, body mass index, or employment and economic situation (p>0.05). It was determined that, in contrast with the healthy group, 70.4% of the women with heroin use disorder had sexual problems and 71.9% of them were not satisfied with their sexual life. It was found that women with heroin use disorder scored significantly lower than healthy controls in FSFI sub-dimensions such as desire, arousal, lubrication, orgasm, satisfaction, and pain, as well as for the total scale, while scores were higher on the BDI scale (p<0.05). Conclusion: Among women with heroin use disorder, sexual functions are adversely affected and depressive symptoms appear to be increased.
{"title":"The effect of heroin use disorder on the sexual functions of women","authors":"M. Dişsiz","doi":"10.5350/DAJPN2018310301","DOIUrl":"https://doi.org/10.5350/DAJPN2018310301","url":null,"abstract":"The effect of heroin use disorder on the sexual functions of women Objective: This study was conducted to evaluate the sexual functions of women with heroin use disorder. Method: This comparative-descriptive and cross-sectional study was carried out at the Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM) of Bakirkoy Training and Research Hospital for Psychiatry Neurology and Neurosurgery. Included in the heroin use disorder group were 57 women aged 18 years or above who presented to AMATEM between June 1, 2014 and December 31, 2014 and received a diagnosis of substance use disorder according to DSM-5. Inclusion criteria were the absence of psychiatric diseases, substance withdrawal symptoms, or mental retardation, being sexually active, not being pregnant or puerperant, and having given consent to participate in the study. Healthy female relatives of 79 female patients who presented to the Gynecology Clinic of the same hospital during the same period were included in the healthy group. The data were collected through an interview form was developed by researchers, Female Sexual Function Index (FSFI), and Beck Depression Inventory (BDI). Results: No difference was determined between the participants in both groups in terms of average age, period of education, body mass index, or employment and economic situation (p>0.05). It was determined that, in contrast with the healthy group, 70.4% of the women with heroin use disorder had sexual problems and 71.9% of them were not satisfied with their sexual life. It was found that women with heroin use disorder scored significantly lower than healthy controls in FSFI sub-dimensions such as desire, arousal, lubrication, orgasm, satisfaction, and pain, as well as for the total scale, while scores were higher on the BDI scale (p<0.05). Conclusion: Among women with heroin use disorder, sexual functions are adversely affected and depressive symptoms appear to be increased.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73309252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-27DOI: 10.5350/DAJPN20183103001
P. Griffiths, Eoghan Quigley, L. Vandam, Jane Mounteney
Dusunen Adam The Journal of Psychiatry and Neurological Sciences, Volume 31, Number 3, September 2018 Each year in the European Drug Report (EDR), the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) produces an overview of trends and developments in the drug situation. Founded in 1993, and based in Lisbon, Portugal, since 1995, the EMCDDA is the designated reference point for drugrelated information in the European Union (EU). It works with all EU member states as well as, by special agreement, with Norway and Turkey. Data are collected annually for a set of standardised indicators that cover both drug demand and drug supply measures. In addition, the EMCDDA, together with Europol, is responsible for the EU’s early warning system on new psychoactive substances (NPS). This three-step mechanism allows for the sharing of information on non-controlled psychoactive substances appearing in Europe that may pose a risk to health similar to drugs controlled under the United Nations Conventions. Should it be merited, information provided to the early warning system may trigger a risk assessment, which is conducted by the EMCDDA’s Scientific Committee. This exercise can potentially lead to a decision for fast track control measures being introduced across the EU. In this editorial, we consider how a more globally joined-up, dynamic and innovative drug market has impacted on drug availability and on drug use problems. In doing so, we build on the commentary and analysis of the Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2018;31:231-237 Guest Editorial / Misafir Editoryal DOI: 10.5350/DAJPN20183103001
{"title":"The challenge of responding to a more globally joined-up, dynamic, and innovative drug market: Reflections from the EMCDDA´s 2018 analysis of the European drug situation","authors":"P. Griffiths, Eoghan Quigley, L. Vandam, Jane Mounteney","doi":"10.5350/DAJPN20183103001","DOIUrl":"https://doi.org/10.5350/DAJPN20183103001","url":null,"abstract":"Dusunen Adam The Journal of Psychiatry and Neurological Sciences, Volume 31, Number 3, September 2018 Each year in the European Drug Report (EDR), the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) produces an overview of trends and developments in the drug situation. Founded in 1993, and based in Lisbon, Portugal, since 1995, the EMCDDA is the designated reference point for drugrelated information in the European Union (EU). It works with all EU member states as well as, by special agreement, with Norway and Turkey. Data are collected annually for a set of standardised indicators that cover both drug demand and drug supply measures. In addition, the EMCDDA, together with Europol, is responsible for the EU’s early warning system on new psychoactive substances (NPS). This three-step mechanism allows for the sharing of information on non-controlled psychoactive substances appearing in Europe that may pose a risk to health similar to drugs controlled under the United Nations Conventions. Should it be merited, information provided to the early warning system may trigger a risk assessment, which is conducted by the EMCDDA’s Scientific Committee. This exercise can potentially lead to a decision for fast track control measures being introduced across the EU. In this editorial, we consider how a more globally joined-up, dynamic and innovative drug market has impacted on drug availability and on drug use problems. In doing so, we build on the commentary and analysis of the Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2018;31:231-237 Guest Editorial / Misafir Editoryal DOI: 10.5350/DAJPN20183103001","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78983196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Yıldızhan, N. Tomruk, Hafize Miray Aytac, H. Yıldırım, Ozge Canbek
Pseudocholinesterase (PCE) deficiency is an inherited condition in which recovery from anesthetic agents like succinylcholine and mivacurium is slow and is complicated with prolonged paralysis of respiratory muscles in susceptible patients. We present a very rare case that we encountered in our practice; the patient is a 29-year-old woman with a 15-year history of schizophrenia with pseudocholinesterase deficiency. Since the detection of PCE levels of all patients eligible for ECT is part of our pre-ECT assessment procedure, we could detect the deficiency before the ECT procedure. We performed modified ECT with propophol and rocuronium instead of succinylcholine as usual. Sugammadex was used for fastening the recovery. Response to treatment which is measured with Positive and Negative Symptom Scale was good and we completed 9 ECT sessions without complication. We suggest further investigation of this topic because screening for PCE levels in pre-ECT assessment may reduce complications of modified ECT with anesthesia.
{"title":"Severe pseudocholinesterase deficiency and ECT: a case report","authors":"E. Yıldızhan, N. Tomruk, Hafize Miray Aytac, H. Yıldırım, Ozge Canbek","doi":"10.5350/DAJPN2018310311","DOIUrl":"https://doi.org/10.5350/DAJPN2018310311","url":null,"abstract":"Pseudocholinesterase (PCE) deficiency is an inherited condition in which recovery from anesthetic agents like succinylcholine and mivacurium is slow and is complicated with prolonged paralysis of respiratory muscles in susceptible patients. We present a very rare case that we encountered in our practice; the patient is a 29-year-old woman with a 15-year history of schizophrenia with pseudocholinesterase deficiency. Since the detection of PCE levels of all patients eligible for ECT is part of our pre-ECT assessment procedure, we could detect the deficiency before the ECT procedure. We performed modified ECT with propophol and rocuronium instead of succinylcholine as usual. Sugammadex was used for fastening the recovery. Response to treatment which is measured with Positive and Negative Symptom Scale was good and we completed 9 ECT sessions without complication. We suggest further investigation of this topic because screening for PCE levels in pre-ECT assessment may reduce complications of modified ECT with anesthesia.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87619032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ozlem Devrim Balaban, Murat Ilhan Atagun, H. Devrimci Ozguven
Information processing abnormalities in schizophrenia and bipolar disorder Objective: Patients with bipolar disorder and schizophrenia exhibit abnormalities in attention, memory, working memory, verbal/visual learning and executive functions. However, many of the tests fail to detect slight changes in cognitive performance due to ceiling effect. It was aimed to determine sensitivity and specificity of the tests that measure information processing in schizophrenia and bipolar disorder in this study. Method: Thirty four patients with schizophrenia, 35 patients with bipolar disorder according to DSM-IV and 33 healthy control subjects matched for age, education level and gender were enrolled to the study. For clinical assessments Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Hamilton Depression Rating Scale, Young Mania Rating Scale, Clinical Global Impression Scale and Abnormal Involuntary Movements Scale were used. All participants performed a battery consisting of tests measuring information processing including Adult Memory and Information Processing Battery (AMIPB), Trail Making Test (TMT) Form A and B, Digit Symbol Coding Task (DST) and Auditory and Visual Reaction Time Tests (RTT). Results: The schizophrenia group had significantly lower performance than the healthy control group in all tests and lower performance than the bipolar disorder group in AMIPBA and B tests, TMT A and B tests. The bipolar disorder group had lower performance than the healthy control group only in DST test. The AMIPB A and B tests were the most sensitive and specific tests in the ROC analysis. Conclusion: Changes in cognitive function might be better monitored by the tests whose sensitivity and specificity are higher. Since psychiatric disorders are highly heterogeneous, measurement tools are important for precise measurements.
{"title":"Information processing abnormalities in schizophrenia and bipolar disorder","authors":"Ozlem Devrim Balaban, Murat Ilhan Atagun, H. Devrimci Ozguven","doi":"10.5350/dajpn2018310202","DOIUrl":"https://doi.org/10.5350/dajpn2018310202","url":null,"abstract":"Information processing abnormalities in schizophrenia and bipolar disorder Objective: Patients with bipolar disorder and schizophrenia exhibit abnormalities in attention, memory, working memory, verbal/visual learning and executive functions. However, many of the tests fail to detect slight changes in cognitive performance due to ceiling effect. It was aimed to determine sensitivity and specificity of the tests that measure information processing in schizophrenia and bipolar disorder in this study. Method: Thirty four patients with schizophrenia, 35 patients with bipolar disorder according to DSM-IV and 33 healthy control subjects matched for age, education level and gender were enrolled to the study. For clinical assessments Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Hamilton Depression Rating Scale, Young Mania Rating Scale, Clinical Global Impression Scale and Abnormal Involuntary Movements Scale were used. All participants performed a battery consisting of tests measuring information processing including Adult Memory and Information Processing Battery (AMIPB), Trail Making Test (TMT) Form A and B, Digit Symbol Coding Task (DST) and Auditory and Visual Reaction Time Tests (RTT). Results: The schizophrenia group had significantly lower performance than the healthy control group in all tests and lower performance than the bipolar disorder group in AMIPBA and B tests, TMT A and B tests. The bipolar disorder group had lower performance than the healthy control group only in DST test. The AMIPB A and B tests were the most sensitive and specific tests in the ROC analysis. Conclusion: Changes in cognitive function might be better monitored by the tests whose sensitivity and specificity are higher. Since psychiatric disorders are highly heterogeneous, measurement tools are important for precise measurements.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80221761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Kıvrak, I. Yagci, Hacer Pasaoglu Yagci, Yasin Taşdelen, M. Aşoglu
Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study Objective: Hyperemesis gravidarum (HG) is a disease characterized by severe nausea and vomiting; it is the most common cause of hospitalization in the first months of pregnancy. The effects of childhood trauma, anxiety types, and exaggeration of somatic sensations on HG have not been defined. In this study, it was aimed to investigate the relationship between HG and factors including depression, anxiety, childhood abuse, and exaggeration of physical sensations. Method: Forty-five pregnant women diagnosed with HG and 45 healthy pregnant women were included in the study. Socio-demographic data form, Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Somatosensory Amplification Scale (SSAS), Childhood Trauma Questionnaire (CTQ), and PregnancyUnique Quantification of Emesis (PUQE) scales were administered to the participants in the study. Results: No significant differences were observed between the groups in relation to socio-demographic data except income levels. The income level of the patient group was lower than that of the control group. Compared to the control group, scores for PUQE (p<0.01), BDI (p<0.01), Trait Anxiety Scale (TAI) (p<0.05), SSAS (p<0.05), and CTQ (p<0.001) were found to be significantly higher in the patient group. According to correlation analysis, while a relation was detected between PUQE scale results and CTQ, BDI, SSAS, and TAI results, no relation was found with the State Anxiety Inventory (SAI). Conclusion: In this study, a history of childhood trauma, depression, exaggeration of somatic sensations, and trait anxiety were found to be more common in individuals with HG. In addition, these factors were also found to be associated with the severity of nausea and vomiting.
{"title":"Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study","authors":"Y. Kıvrak, I. Yagci, Hacer Pasaoglu Yagci, Yasin Taşdelen, M. Aşoglu","doi":"10.5350/DAJPN2018310205","DOIUrl":"https://doi.org/10.5350/DAJPN2018310205","url":null,"abstract":"Hyperemesis gravidarum is associated with childhood trauma, depression, trait anxiety, and somatization: a case-control study Objective: Hyperemesis gravidarum (HG) is a disease characterized by severe nausea and vomiting; it is the most common cause of hospitalization in the first months of pregnancy. The effects of childhood trauma, anxiety types, and exaggeration of somatic sensations on HG have not been defined. In this study, it was aimed to investigate the relationship between HG and factors including depression, anxiety, childhood abuse, and exaggeration of physical sensations. Method: Forty-five pregnant women diagnosed with HG and 45 healthy pregnant women were included in the study. Socio-demographic data form, Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Somatosensory Amplification Scale (SSAS), Childhood Trauma Questionnaire (CTQ), and PregnancyUnique Quantification of Emesis (PUQE) scales were administered to the participants in the study. Results: No significant differences were observed between the groups in relation to socio-demographic data except income levels. The income level of the patient group was lower than that of the control group. Compared to the control group, scores for PUQE (p<0.01), BDI (p<0.01), Trait Anxiety Scale (TAI) (p<0.05), SSAS (p<0.05), and CTQ (p<0.001) were found to be significantly higher in the patient group. According to correlation analysis, while a relation was detected between PUQE scale results and CTQ, BDI, SSAS, and TAI results, no relation was found with the State Anxiety Inventory (SAI). Conclusion: In this study, a history of childhood trauma, depression, exaggeration of somatic sensations, and trait anxiety were found to be more common in individuals with HG. In addition, these factors were also found to be associated with the severity of nausea and vomiting.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74006091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychiatric presentation of hypoxic ischemic encephalopathy occurring after a violent suicide attempt: a case of hanging","authors":"Mehmet Hamdi Örüm, O. Eğilmez","doi":"10.5350/DAJPN2018310214","DOIUrl":"https://doi.org/10.5350/DAJPN2018310214","url":null,"abstract":"","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"119 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73693133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Batıgün, N. Gor, Burcu Komurcu, Ipek Senkal Erturk
Cyberchondria Scale (CS): Development, validity and reliability study Objective: The aim of the current study is to develop culture specific, multidimensional and self-report Cyberchondria Scale (CS) which can be used to evaluate one’s emotional, cognitive and behavioral tendency to cyberchondria and to determine the psychometric properties of this scale. Method: The study was conducted with two different samples consisted of Internet users. To investigate the factor structure, the first sample was composed of 250 (49.6% women, 50.4% men) individuals aged between 18 and 65. The second sample in which confirmatory factor analysis (CFA) was conducted consisted of 360 (61.1% women, 38.3% men) individuals aged between 18 and 65. In addition to CS, Internet Addiction Scale (IAS), Brief Symptom Inventory (BSI) and Health Anxiety Inventory (HAI) were
{"title":"Cyberchondria Scale (CS): Development, validity and reliability study","authors":"A. Batıgün, N. Gor, Burcu Komurcu, Ipek Senkal Erturk","doi":"10.5350/DAJPN2018310203","DOIUrl":"https://doi.org/10.5350/DAJPN2018310203","url":null,"abstract":"Cyberchondria Scale (CS): Development, validity and reliability study Objective: The aim of the current study is to develop culture specific, multidimensional and self-report Cyberchondria Scale (CS) which can be used to evaluate one’s emotional, cognitive and behavioral tendency to cyberchondria and to determine the psychometric properties of this scale. Method: The study was conducted with two different samples consisted of Internet users. To investigate the factor structure, the first sample was composed of 250 (49.6% women, 50.4% men) individuals aged between 18 and 65. The second sample in which confirmatory factor analysis (CFA) was conducted consisted of 360 (61.1% women, 38.3% men) individuals aged between 18 and 65. In addition to CS, Internet Addiction Scale (IAS), Brief Symptom Inventory (BSI) and Health Anxiety Inventory (HAI) were","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83267556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carmen Maura Carrillo de Albornoz, M. Guerrero-Jiménez, L. Gutiérrez-Rojas
Sleep-related eating disorder caused by zolpidem: case report and review of the literature Sleep-related eating disorder (SRED) is a status characterized by recurrent episodes of eating high caloric foods and sometimes even toxic products at the transition from night-time sleep to arousal. The case presented is secondary to treatment with zolpidem, a hypnotic whose prescription rate has increased worldwide over the past few years. The authors report a case of SRED caused by zolpidem with important repercussions on the sleep structure and quality of life of our patient. The night eating episodes ceased promptly with zolpidem discontinuation, the sleep structure improved and the dayand night-time consequences disappeared. As in very few reported cases of zolpidem-induced SREDs, our patient had been suffering from parasomnia for a long time before the diagnosis. Reaching an understanding of the mechanism producing this type of parasomnias can be a guide for choosing the candidate profile before starting a zolpidem treatment. Active exclusion of symptoms suggestive of SREDs in patients under zolpidem treatment can avoid a significant deterioration in the quality of life of our patients. To our knowledge, there are no data focusing on the risk of parasomnias as a function of the sedative-hypnotic agent chosen. Here we present a case that may help address this issue.
{"title":"Sleep-related eating disorder caused by zolpidem: case report and review of the literature","authors":"Carmen Maura Carrillo de Albornoz, M. Guerrero-Jiménez, L. Gutiérrez-Rojas","doi":"10.5350/DAJPN2018310207","DOIUrl":"https://doi.org/10.5350/DAJPN2018310207","url":null,"abstract":"Sleep-related eating disorder caused by zolpidem: case report and review of the literature Sleep-related eating disorder (SRED) is a status characterized by recurrent episodes of eating high caloric foods and sometimes even toxic products at the transition from night-time sleep to arousal. The case presented is secondary to treatment with zolpidem, a hypnotic whose prescription rate has increased worldwide over the past few years. The authors report a case of SRED caused by zolpidem with important repercussions on the sleep structure and quality of life of our patient. The night eating episodes ceased promptly with zolpidem discontinuation, the sleep structure improved and the dayand night-time consequences disappeared. As in very few reported cases of zolpidem-induced SREDs, our patient had been suffering from parasomnia for a long time before the diagnosis. Reaching an understanding of the mechanism producing this type of parasomnias can be a guide for choosing the candidate profile before starting a zolpidem treatment. Active exclusion of symptoms suggestive of SREDs in patients under zolpidem treatment can avoid a significant deterioration in the quality of life of our patients. To our knowledge, there are no data focusing on the risk of parasomnias as a function of the sedative-hypnotic agent chosen. Here we present a case that may help address this issue.","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80435370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emergence of stuttering in an attention deficit hyperactivity disorder patient treated with methylphenidate","authors":"M. Çopur, Sidar Copur","doi":"10.5350/dajpn2018310212","DOIUrl":"https://doi.org/10.5350/dajpn2018310212","url":null,"abstract":"","PeriodicalId":11480,"journal":{"name":"Dusunen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80966098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：